View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 73.24M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.70 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -28.77M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 76.43% |
| Profit Margin (Quarterly) | -26.55% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 10.90M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 0.0886 |
| PE Ratio | -- |
| Price to Book Value | -- |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | -3.255 |
| Free Cash Flow (Quarterly) | 0.114M |
| Return on Equity | Upgrade |
View All VVUS News
News
-
WireHeadlineTime (ET)
-
MT Newswires07/08 09:06
-
SA Breaking News07/08 07:04
-
MT Newswires07/08 04:50
-
Globe Newswire07/07 16:49
-
Yahoo06/10 06:00
-
MT Newswires06/09 17:41
-
SA Breaking News06/09 06:49
-
Globe Newswire06/02 07:30
-
Yahoo05/22 22:21
-
Yahoo05/08 06:05
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 02/26/2020 16:30 EST | Misc | VIVUS Inc Fourth Quarter Earnings Conference Call in 2019 |
| 02/26/2020 | Earnings | VIVUS Inc Fourth Quarter Earnings in 2019 Release |
| 11/05/2019 16:30 EST | Misc | VIVUS Inc Third Quarter Earnings Conference Call for 2019 |
| 11/05/2019 | Earnings | VIVUS Inc Third Quarter Earnings in 2019 Release |
| 08/06/2019 16:30 EDT | Misc | VIVUS Inc Second Quarter Earnings Conference Call in 2019 |
| 08/06/2019 | Earnings | VIVUS Inc Second Quarter Earnings in 2019 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.vivus.com
- Investor Relations URL: http://ir.vivus.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Feb. 26, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 0.61 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- VVUS Tweets Stocktwits
Advertisement
